Vontobel Asset Management Inc. cut its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 5.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 113,119 shares of the medical research company’s stock after selling 6,705 shares during the period. Vontobel Asset Management Inc. owned 0.05% of Edwards Lifesciences worth $16,465,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of EW. BlackRock Inc. increased its position in shares of Edwards Lifesciences by 1.6% in the 1st quarter. BlackRock Inc. now owns 15,653,522 shares of the medical research company’s stock valued at $2,183,978,000 after acquiring an additional 242,785 shares during the period. FMR LLC increased its position in shares of Edwards Lifesciences by 32.9% in the 2nd quarter. FMR LLC now owns 6,714,684 shares of the medical research company’s stock valued at $977,456,000 after acquiring an additional 1,663,511 shares during the period. Brown Advisory Inc. increased its position in shares of Edwards Lifesciences by 5.8% in the 2nd quarter. Brown Advisory Inc. now owns 3,866,016 shares of the medical research company’s stock valued at $562,775,000 after acquiring an additional 211,258 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of Edwards Lifesciences by 5.3% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,147,510 shares of the medical research company’s stock valued at $312,614,000 after acquiring an additional 107,676 shares during the period. Finally, Royal Bank of Canada increased its position in shares of Edwards Lifesciences by 9.1% in the 1st quarter. Royal Bank of Canada now owns 1,550,377 shares of the medical research company’s stock valued at $216,309,000 after acquiring an additional 129,036 shares during the period. 82.12% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts recently issued reports on the company. ValuEngine downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, June 6th. Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a report on Saturday, July 14th. BMO Capital Markets upped their price target on shares of Edwards Lifesciences to $162.00 and gave the company an “outperform” rating in a report on Tuesday, July 10th. Morgan Stanley upped their price target on shares of Edwards Lifesciences from $138.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, July 27th. Finally, Sanford C. Bernstein began coverage on shares of Edwards Lifesciences in a report on Wednesday, June 27th. They issued a “market perform” rating and a $165.00 price target on the stock. One analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $152.45.

In related news, VP Huimin Wang sold 3,800 shares of the firm’s stock in a transaction dated Monday, August 6th. The shares were sold at an average price of $144.99, for a total value of $550,962.00. Following the transaction, the vice president now directly owns 88,483 shares of the company’s stock, valued at approximately $12,829,150.17. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,500 shares of the firm’s stock in a transaction dated Wednesday, June 13th. The shares were sold at an average price of $150.00, for a total transaction of $825,000.00. Following the completion of the transaction, the vice president now directly owns 25,512 shares in the company, valued at $3,826,800. The disclosure for this sale can be found here. Over the last three months, insiders have sold 122,075 shares of company stock worth $17,626,656. Corporate insiders own 1.84% of the company’s stock.

Shares of EW stock traded up $1.85 during mid-day trading on Friday, hitting $142.40. 5,855 shares of the stock were exchanged, compared to its average volume of 1,000,423. The company has a quick ratio of 1.47, a current ratio of 1.86 and a debt-to-equity ratio of 0.19. Edwards Lifesciences Corp has a 52-week low of $100.20 and a 52-week high of $156.87. The firm has a market cap of $29.27 billion, a P/E ratio of 37.09, a PEG ratio of 1.93 and a beta of 0.57.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The business had revenue of $972.00 million for the quarter, compared to analyst estimates of $968.32 million. During the same period in the prior year, the company posted $1.08 EPS. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. analysts anticipate that Edwards Lifesciences Corp will post 4.67 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Recommended Story: Marijuana Stocks Investing Considerations

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.